Overview

Genentech is an American biotechnology company headquartered in South San Francisco, California, and an independent subsidiary of Roche. Founded in 1976 by venture capitalist Robert A. Swanson and biochemist Herbert W. Boyer, it is widely regarded as one of the first modern biotechnology companies. Its creation linked venture financing with recombinant-DNA research at a time when genetic engineering was moving from academic laboratories toward commercial medicine. The company’s early scientific achievements established much of its long-term identity. Boyer and Stanley Cohen had demonstrated methods for cutting and recombining DNA, and Boyer subsequently worked with Arthur Riggs, Keiichi Itakura, David Goeddel, Dennis Kleid, and other researchers. In 1977, the group successfully expressed a human gene in bacteria to produce somatostatin. In 1978, Genentech researchers produced synthetic human insulin, helping demonstrate that recombinant DNA could support the manufacture of human therapeutics at industrial scale. Eli Lilly later led development and regulatory commercialization of the recombinant insulin product, marketed as Humulin, which became the first genetically engineered human therapeutic approved in the United States. Genentech’s first marketed product was Protropin, a recombinant human growth hormone product. The company subsequently built a portfolio spanning hematology, oncology, ophthalmology, respiratory disease, immunology, neurology, and rare diseases. Its products and research programs helped establish therapeutic antibodies, recombinant proteins, targeted cancer medicines, antibody-drug conjugates, and other biologic platforms as important components of pharmaceutical research. Major brands associated with Genentech include Activase, Rituxan, Herceptin, Avastin, Lucentis, Actemra, Perjeta, Kadcyla, Gazyva, Tecentriq, Ocrevus, Hemlibra, and Polivy. The company developed through a combination of internal research, licensing, alliances, and acquisitions. In 1990, F. Hoffmann-La Roche acquired a majority interest in Genentech, while Genentech continued to operate with substantial scientific and organizational independence. In 2006, Genentech acquired Tanox, strengthening its economic position in Xolair, a drug developed with Novartis and Tanox. Roche completed the acquisition of Genentech in 2009 by purchasing the remaining publicly held shares for approximately $46.8 billion, converting Genentech into a wholly owned subsidiary. Following the transaction, Genentech retained an independent operating identity in the United States, while Genentech Research and Early Development became an independent research center within Roche. Genentech has continued to use collaborations as a central business model. Its relationships have included Roche and GlycArt, the University of California, San Francisco, 23andMe, NewLink Genetics, Nimbus Therapeutics, Epizyme, Carmot Therapeutics, and BioLineRx. These arrangements have covered antibody development, genomics, data science, small-molecule discovery, immuno-oncology, and combination therapies. The company’s facilities have included sites in South San Francisco, Vacaville, Oceanside, California, and Hillsboro, Oregon, as well as international manufacturing operations and partnerships. In the 2020s, Genentech remained focused on innovative medicines for serious and complex diseases, with oncology and immunology among its most visible areas. Roche announced manufacturing changes affecting Genentech facilities, including the planned closure of the South San Francisco manufacturing operation and the 2024 sale of the Vacaville site to Lonza. Genentech’s present positioning combines a legacy of foundational biotechnology research with Roche’s global development, manufacturing, and commercial infrastructure.

History

Genentech emerged from the convergence of recombinant-DNA science and venture capital in the 1970s. Robert A. Swanson approached Herbert W. Boyer after Boyer’s academic work with Stanley Cohen had helped establish techniques for manipulating DNA. The company was incorporated in 1976, and its early research team expanded through collaborations with scientists including Arthur Riggs, Keiichi Itakura, David Goeddel, and Dennis Kleid. The scientific program produced two foundational demonstrations. In 1977, Genentech researchers expressed a human gene in bacteria to make somatostatin. The following year, the company reported the production of synthetic human insulin. Eli Lilly partnered with Genentech to develop and manufacture the insulin product, Humulin, which received U.S. approval in 1982 and became the first approved genetically engineered human therapeutic. Genentech’s own first marketed product was Protropin, a recombinant growth hormone product introduced in the 1980s. During the 1980s and 1990s, Genentech broadened its platform from recombinant proteins into thrombolytics, growth hormones, cytokines, and therapeutic antibodies. Activase, Pulmozyme, Nutropin, Actimmune, Rituxan, and Herceptin illustrated the company’s movement toward medicines for cardiovascular disease, cystic fibrosis, immune disorders, blood cancers, and solid tumors. In 1982, Genentech and Corning Glass Works also established Genencor to pursue industrial enzyme applications of recombinant DNA. Roche became a strategic shareholder in 1990 by acquiring a majority stake. The relationship allowed Genentech to preserve a distinctive research-driven identity while gaining access to Roche’s international resources. Genentech continued to develop products in oncology and other specialty areas, including Avastin, Tarceva, Lucentis, Xolair, and later Actemra, Zelboraf, Perjeta, Kadcyla, Gazyva, Tecentriq, Ocrevus, Hemlibra, and Polivy. The company used acquisitions and partnerships to supplement internal discovery. It acquired Tanox in 2006 after participating in the development of Xolair with Novartis and Tanox. Genentech also entered collaborations involving obinutuzumab, neurological small-molecule discovery, genomic data, checkpoint inhibitors, computational drug discovery, epigenetic therapies, and antibody combinations. In 2014, it acquired Seragon to obtain a small-molecule oncology pipeline. Genentech faced significant legal and public-policy controversies. A patent dispute with UCSF concerning Protropin was settled in 1999 for $200 million. In 2009, media reporting raised questions about the use of company-prepared language in congressional statements during health-care reform negotiations. The company also voluntarily withdrew Raptiva from the U.S. market after safety reports involving progressive multifocal leukoencephalopathy. Roche completed its full acquisition of Genentech in March 2009. Genentech thereafter operated as Roche’s wholly owned U.S. subsidiary, while maintaining a separate brand and operating culture. Genentech Research and Early Development functions as an independent research center within Roche. Its South San Francisco headquarters remains a major biotechnology center, supported by manufacturing and research facilities in California and Oregon and by Roche’s wider global network. More recent changes have included plans to close South San Francisco manufacturing operations, expand Oceanside capacity, and sell the Vacaville site to Lonza.

2017
Ocrevus and Hemlibra expand the portfolio
[1]Genentechen.wikipedia.org
The company adds major treatments for multiple sclerosis and hemophilia A.
2016
Tecentriq is introduced
[1]Genentechen.wikipedia.org
Atezolizumab becomes Genentech’s first anti-PD-L1 immunotherapy product.
2013
Kadcyla and Gazyva are approved
[1]Genentechen.wikipedia.org
The approvals expand Genentech’s antibody-drug conjugate and hematology portfolios.
2009
Roche completes the acquisition
[1]Genentechen.wikipedia.org
Genentech becomes a wholly owned Roche subsidiary.
2006
Tanox is acquired
[1]Genentechen.wikipedia.org
Genentech completes its first acquisition, obtaining Tanox and related economic rights connected to Xolair.
1998
Herceptin is approved
[1]Genentechen.wikipedia.org
Trastuzumab is approved for HER2-positive metastatic breast cancer and becomes a defining targeted oncology medicine.
1997
Rituxan enters the oncology portfolio
[1]Genentechen.wikipedia.org
Rituximab receives approval for certain non-Hodgkin lymphomas, strengthening Genentech’s position in cancer treatment.
1990
Roche acquires a majority stake
[1]Genentechen.wikipedia.org
F. Hoffmann-La Roche acquires majority ownership of Genentech.
1982
Humulin receives U.S. approval
[1]Genentechen.wikipedia.org
Eli Lilly’s recombinant human insulin, developed with Genentech, becomes the first approved genetically engineered human therapeutic.
1978
Synthetic human insulin produced
[1]Genentechen.wikipedia.org
The company reports production of synthetic human insulin using recombinant-DNA methods.
1977
Human gene expression in bacteria
[1]Genentechen.wikipedia.org
Genentech researchers produce somatostatin by expressing a human gene in bacteria.
1976
Genentech is founded
[1]Genentechen.wikipedia.org
Robert A. Swanson and Herbert W. Boyer establish Genentech to commercialize recombinant-DNA biotechnology.

Products and positioning

Research-driven biotechnology innovator focused on biologic and targeted medicines for serious diseases, particularly cancer, immunological disorders, neurological conditions, and rare diseases.

Recombinant insulin · 1982
Humulin
Recombinant human insulin developed with Genentech and commercialized by Eli Lilly. Its U.S. approval in 1982 demonstrated that genetically engineered microorganisms could produce a human therapeutic at commercial scale.
Oncology and immunology biologic · 1997
Rituxan
Rituximab is a monoclonal antibody directed at CD20. It was introduced for certain non-Hodgkin lymphomas and later gained uses including rheumatoid arthritis, becoming one of the foundational antibody therapies in hematology and immunology.
Targeted oncology biologic · 1998
Herceptin
Trastuzumab is an antibody targeting HER2. It transformed treatment for HER2-positive breast cancer and has also been used in other HER2-expressing cancers, including certain gastric cancers.
Anti-VEGF oncology biologic · 2004
Avastin
Bevacizumab blocks vascular endothelial growth factor and limits tumor blood-vessel formation. Its approved uses have included colorectal, lung, kidney, brain, and other cancers, with indications varying by jurisdiction and over time.
Ophthalmic biologic · 2006
Lucentis
Ranibizumab is an anti-VEGF injection for neovascular eye diseases, including wet age-related macular degeneration. It extended Genentech’s anti-VEGF expertise from oncology into ophthalmology.
Immunology biologic · 2010
Actemra
Tocilizumab inhibits the interleukin-6 receptor and is used in inflammatory and autoimmune conditions, including rheumatoid arthritis. It was the first approved IL-6 receptor-inhibiting monoclonal antibody.
Antibody-drug conjugate · 2013
Kadcyla
Ado-trastuzumab emtansine combines the HER2-targeting antibody trastuzumab with the cytotoxic payload DM1. The design delivers chemotherapy to HER2-positive cancer cells and established a major Genentech antibody-drug conjugate platform.
Immuno-oncology biologic · 2016
Tecentriq
Atezolizumab is an anti-PD-L1 antibody used in several advanced cancers. It expanded Genentech’s oncology portfolio into checkpoint inhibition and has been studied in combination with chemotherapy and other targeted medicines.
Neurology biologic · 2017
Ocrevus
Ocrelizumab is a CD20-directed antibody for multiple sclerosis. Its approval covered both relapsing forms and primary progressive multiple sclerosis, for which there had previously been no approved disease-modifying treatment.
Hematology biologic · 2017
Hemlibra
Emicizumab is a bispecific antibody for hemophilia A. Developed with Chugai Pharmaceutical, it uses a non-factor replacement mechanism to support clotting and broaden preventive treatment options.

Controversies

2009
Use of company lobbying language in congressional statements
News reporting said that language prepared by Genentech lobbyists appeared in statements by members of Congress during the U.S. health-care reform debate, raising concerns about the transparency of corporate influence.
Source
1999
UCSF Protropin patent dispute
The University of California, San Francisco sued Genentech over alleged use of university-developed technology connected with recombinant human growth hormone and Protropin. Genentech disputed the claim, and the matter was resolved through a $200 million settlement.
Source

Brand decisions

2023
Restructure manufacturing footprintStrategy
Background
Roche and Genentech reviewed manufacturing capacity and site requirements in the United States.
Action taken
Genentech announced plans to close its South San Francisco manufacturing facility while expanding capacity in Oceanside.
Aftermath
The decision pointed to a more concentrated manufacturing network, although the supplied sources do not specify the full employment or capacity impact.
Source
2014
Acquire Seragon TherapeuticsM&A
Background
Genentech sought to expand its oncology pipeline with Seragon’s small-molecule drug candidates.
Action taken
Genentech acquired Seragon for $725 million upfront, with additional contingent payments linked to development outcomes.
Aftermath
The transaction added experimental cancer medicines and strengthened Genentech’s precision-oncology research portfolio.
Upfront consideration. $725 million (2014)
Source
2009
Accept Roche’s full acquisitionM&A
Background
Roche already held a majority stake and sought to acquire the remaining Genentech shares.
Action taken
Roche purchased the outstanding shares and made Genentech a wholly owned subsidiary.
Aftermath
Genentech retained its operating identity in the United States and continued to function as a distinct Roche biotechnology organization.
Transaction value. Approximately $46.8 billion (2009)
Source

Recent events

2024
Roche announces sale of the Vacaville manufacturing site to Lonza[1]Genentechen.wikipedia.org
M&A
Lonza announced an agreement to acquire Genentech’s Vacaville, California manufacturing site from Roche for approximately $1.2 billion.
2023
Genentech plans changes to South San Francisco manufacturing operations[1]Genentechen.wikipedia.org
Other
Genentech announced plans to close its South San Francisco manufacturing facility while expanding manufacturing capabilities at its Oceanside site.
2014
Genentech acquires Seragon for oncology candidates[1]Genentechen.wikipedia.org
M&A
Genentech agreed to acquire Seragon Therapeutics for $725 million in upfront cash, with additional potential payments tied to development success. The transaction added small-molecule cancer drug candidates to Genentech’s pipeline.
2009
Genentech becomes a wholly owned Roche subsidiary[1]Genentechen.wikipedia.org
M&A
Roche completed its purchase of the Genentech shares it did not already own in a transaction valued at approximately $46.8 billion. Genentech continued operating as an independent subsidiary within Roche.
2009
Raptiva withdrawn from the U.S. market[1]Genentechen.wikipedia.org
Recall · Regulation
Genentech voluntarily withdrew Raptiva after reports associated the psoriasis medicine with progressive multifocal leukoencephalopathy, a serious neurological infection.

Related entries

Roche